Menu
ÚHKT

Impaktované publikace

[1]

Saussele, S.; Richter, J.; Guilhot, J.; Gruber, F.X.; Hjorth-Hansen, H.; Almeida, A.; Janssen, J.J.W.M.; Mayer, J.; Koskenvesa, P.; Panayiotidis, P.; Olsson-Strömberg, U.; Martinez-Lopez, J.; Rousselot, P.; Vestergaard, H.; Ehrencrona, H.; Kairisto, V.; Machová Poláková, K.; Müller, M.C.; Mustjoki, S.; Berger, M.G.; Fabarius, A.; Hofmann, W.-K.; Hochhaus, A.; Pfirrmann, M.; Mahon, F.-X.; Ossenkoppele, G.; Pagoni, M.N.; Söderlund, S.; Escoffre-Barbe, M.; Etienne, G.; Dengler, J.; Huguet, F.; von Bubnoff, N.; Klamova, H.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

[rok vydání 2018, impact factor 35.386 ]

[2]

Porkka, K.; Koskenvesa, P.; Lundán, T.; Rimpiläinen, J.; Mustjoki, S.; Smykla, R.; Wild, R.; Luo, R.; Arnan, M.; Brethon, B.; Eccersley, L.; Hjorth-Hansen, H.; Höglund, M.; Klamová, H.; Knutsen, H.; Parikh, S.; Raffoux, E.; Gruber, F.; Brito-Babapulle, F.; Dombret, H.; Duarte, R.F.; Elonen, E.; Paquette, R.; Zwaan, C.M.; Lee, F.Y.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

[rok vydání 2008, impact factor 10.432]

[3]

Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Brouckova, A.; Horner, D.; Iacono, M.; Castagnetti, F.; Gugliotta, G.; Palandri, F.; Papayannidis, C.; Iacobucci, I.; Venturi, C.; Bochicchio, M.T.; Klamova, H.; Cattina, F.; Russo, D.; Bresciani, P.; Binotto, G.; Giannini, B.; Kohlmann, A.; Haferlach, T.; Roller, A.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

[rok vydání 2013, impact factor 9.775 ]

[4]

Moravcová, J.; Nádvorníková, S.; Lukášová, M.; Klamová, H.

Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia

[rok vydání 2006, impact factor 8.782]

[5]

Machova Polakova, K.; Zizkova, H.; Zuna, J.; Motlova, E.; Hovorkova, L.; Gottschalk, A.; Glauche, I.; Koblihova, J.; Pecherkova, P.; Klamova, H.; Stastna Markova, M.; Srbova, D.; Benesova, A.; Polivkova, V.; et al.

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

[rok vydání 2020, impact factor 8.665 ]

[6]

Vonka, V.; Humlova, Z.; Klamova, H.; Kujovska-Krcmova, L.; Petrackova, M.; Hamsikova, E.; Krmencikova-Fliegl, M.; Duskova, M.; Roth, Z.

Kynurenine and uric acid levels in chronic myeloid leukemia patients

[rok vydání 2014, impact factor 7.644 ]

[7]

Srutova, K.; Curik, N.; Burda, P.; Savvulidi, F.; Silvestri, G.; Trotta, R.; Klamova, H.; Pecherkova, P.; Sovova, Z.; Koblihova, J.; Stopka, T.; Perrotti, D.; Machova Polakova, K.

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

[rok vydání 2018, impact factor 7.570 ]

[8]

Jaruskova, M.; Curik, N.; Hercog, R.; Polivkova, V.; Motlova, E.; Benes, V.; Klamova, H.; Pecherkova, P.; Belohlavkova, P.; Vrbacky, F.; Machova Polakova, K.

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

[rok vydání 2017, impact factor 6.217 ]

[9]

Racil, Z.; Koritakova, E.; Sacha, T.; Klamova, H.; Belohlavkova, P.; Faber, E.; Rea, D.; Malaskova, L.; Prochazkova, J.; Zackova, D.; Voglova, J.; Waclaw, J.; Cetkovsky, P.; Zak, P.; Mayer, J.

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

[rok vydání 2018, impact factor 6.137 ]

[10]

Linhartova, J.; Hovorkova, L.; Soverini, S.; Benesova, A.; Jaruskova, M.; Klamova, H.; Zuna, J.; Machova Polakova, K.

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing

[rok vydání 2015, impact factor 5.888 ]

[11]

Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Linhartova, J.; Castagnetti, F.; Gugliotta, G.; Papayannidis, C.; Mancini, M.; Klamova, H.; Salvucci, M.; Crugnola, M.; Iurlo, A.; Albano, F.; Russo, D.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

[rok vydání 2016, impact factor 5.168 ]

[12]

Zackova, D.; Klamova, H.; Dusek, L.; Muzik, J.; Machova Polakova, K.; Moravcova, J.; Jurcek, T.; Dvorakova, D.; Racil, Z.; Pospisil, Z.; Oltova, A.; Michalova, K.; Brezinova, J.; Razga, F.; Doubek, M.; Cetkovsky, P.; Trneny, M.; Mayer, J.

Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

[rok vydání 2010, impact factor 4.671 ]

[13]

Machová Poláková, K.; Lopotová, T.; Klamová, H.; Burda, P.; Trněný, M.; Stopka, T.; Moravcová, J.

Expression patterns of microRNAs associated with CML phases and their disease related targets

[rok vydání 2011, impact factor 3.993 ]

[14]

Racil, Z.; Klamova, H.; Voglova, J.; Faber, E.; Razga, F.; Zackova, D.; Buresova, L.; Cetkovsky, P.; Mayer, J.

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

[rok vydání 2010, impact factor 3.576]

[15]

Pavlik, T.; Janousova, E.; Mayer, J.; Indrak, K.; Jarosova, M.; Klamova, H.; Zackova, D.; Voglova, J.; Faber, E.; Karas, M.; Machova Polakova, K.; Racil, Z.; Demeckova, E.; Demitrovicova, L.; Tothova, E.; Chudej, J.; Markuljak, I.; Cmunt, E.; Kozak, T.; Muzik, J.; Dusek, L.

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

[rok vydání 2013, impact factor 3.477 ]

[16]

Smetana, K.; Klamová, H.; Pluskalová, M.; Stöckbauer, P.; Hrkal, Z.:

To the intranucleolar translocation of AgNORs in leukemic early granulocytic and plasmacytic precursors.

[rok vydání 2006, impact factor 3.220]

[17]

Haškovec, C.; Ponzetto, C.; Polák, J.; Maritano, D.; Zemanová, Z.; Serra, A.; Michalová, K.; Klamová, H.; Čermák, J.; Saglio, G.

P230 BCR/ABL protein may be associated with an acute leukaemia phenotype

[rok vydání 2006, impact factor 3.209]

[18]

Machová Poláková, K.; Polívková, V.; Rulcová, J.; Klamová, H.; Jurček, T.; Dvořáková, D.; Žáčková, D.; Pospíšil, Z.; Mayer, J.; Moravcová, J.

Constant BCR-ABL transcript level less than or equal 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

[rok vydání 2009, impact factor 3.198]

[19]

Polák, J.; Zemanová, Z.; Michalová, K.; Klamová, H.; Čermák, J.; Haškovec, C.

A new case of chronic myeloid leukemia (CML) in myeloid blast crisis with an atypical (b3/a3) junction of the BCR/ABL gene

[rok vydání 2006, impact factor 3.163]

[20]

Machova Polakova, K.; Kulvait, V.; Benesova, A.; Linhartova, J.; Klamova, H.; Jaruskova, M.; de Benedittis, C.; Haferlach, T.; Baccarani, M.; Martinelli, G.; Stopka, T.; Ernst, T.; Hochhaus, A.; Kohlmann, A.; Soverini, S.

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

[rok vydání 2014, impact factor 3.141 ]